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Cardiovascular diseases in addition to cancer
and infectious diseases are the leading causes of
death in the world. According to WHO data, it is
estimated that in 2012, 17.5 million people died of
cardiovascular disease worldwide or of complica-
tions, which is 31% of all deaths. It was assessed
that 7.4 million of these deaths were due to ischemic
heart disease and 6.7 million were caused by stroke.
The highest number of deaths, about 13.2 million,
was reported in low or middle-income countries. It
has been estimated that of the 16 million deaths
caused by non-infectious diseases, among the popu-
lation below 70 years 82% refer to low- and middle-
income countries, 37% were caused by cardiovascu-
lar diseases (1, 2).
The possibility of cardiovascular disease can
be reduced by eliminating certain factors that
increase the likelihood of its occurrence. Tobacco
smoking, abnormal lipid levels, abnormal diet,
physical inactivity, obesity, and diabetes are the
main risk factors (3). People with cardiovascular
disease or who are at high risk of cardiovascular dis-
ease (due to the presence of one or more risk factors
such as hypertension, diabetes, hyperlipidemia)
must be subjected to early diagnosis and therapy.
Then the correct system of treatment should be
selected with the use of various individually indicat-
ed pharmaceutical preparations. The most common-
ly used in polytherapy pharmacological classes are
antithrombotic agents, β-blockers, angiotensin con-
verting enzyme inhibitors (ACEI), angiotensin
receptor blockers (ARBs), statins, diuretics, and cal-
cium channel blockers.
Such a large number of different substances
requires the optimization of the treatment in terms of
its effectiveness and potential side effects. In the
majority of cases, patients treated for cardiovascular
disease are forced to take 2, 3 and sometimes 4 dif-
ferent pharmaceutical preparations whose synergis-
tic effects improve cardiovascular system. In addi-
tion, you may need to take other medicines that are
not directly related to cardiovascular treatment, such
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as anti-inflammatory drugs, analgesic drugs, or anti-
histamines.
In 2003, Wald and Law introduced the concept
of a polypill (4). It referred to the pharmaceutical
preparation composed of a statin, for example ator-
vastatin (daily dose 10 mg) or simvastatin (40 mg),
three blood pressure lowering drugs (for example
thiazide, a β blocker, and an angiotensin converting
enzyme inhibitor) each at half standard dose, folic
acid (0.8 mg) and acetylsalicylic acid (75 mg). Since
then there has been a clear development of the con-
cept of polypills, but the basic character of its com-
position remained unchanged. In many countries, a
number of randomized studies have been carried out
to determine the effect of the use of this type of drug
in a particular group of patients compared to place-
bo or to polytherapy with one or two-component
preparations. 
Effects of clinical studies 
Studies of TIPS and TIPS 2 were conducted on
a group of 2053 patients at the age of 45-80 and
showed that administration of a polypill composed
of hydrochlorothiazide, atenolol, ramipril, simvas-
tatin, and acetylsalicylic acid brings measurable
effects in the form of lowering cholesterol and blood
pressure (4, 6). A more effective decrease in choles-
terol levels has been reported in patients with dia-
betes. The occurrence of side effects statistically did
not differ from the value seen in the treatment group
taking one-component drugs, which, according to
the authors, contradicts the theory that the increase
in the amount of components in a polypill increases
the likelihood of side effects. The authors assessed
that the use of a polypill may reduce the risk of car-
diovascular events by up to 60%, which is the basis
for further research.
In 2008-2009, the Pill Collaborative Group
conducted the study of 378 participants aged 50-70
years. The effects of a polypill composed of acetyl-
salicylic acid, lisinopril, hydrochlorothiazide and
simvastatin on the reduction of systolic blood pres-
sure and lipid level were evaluated. After 12 weeks
the obtained results were statistically evaluated and
a decrease in cholesterol level and systolic blood
pressure was observed. At the same time, side
effects were observed in about 17% of the patients
(7).
In the case of studies conducted by Malek-
zadeh and Wald in groups of patients aged over 50
years, a decrease of systolic blood pressure and lipid
levels was also observed (8, 9). The analysis of the
results obtained after the application of a polypill
composed of acetylsalicylic acid, enalapril, atorvas-
tatin, and hydrochlorothiazide showed a statistically
significant decrease of these parameters that was not
as clear as in the case of a Waldís polypill (amlodip-
ine, losartan, hydrochlorothiazide, and simvastatin).
This may be due to the replacement of one antihy-
pertensive drug (enalapril) by two drugs (amlodip-
ine and losartan).
Slightly different results of studies on the
application of polypills are presented in publications
where the polypills of similar composition were
used (10-12). In both cases, the authors underline
the high acceptability of polypills among physicians
and patients and a smaller percentage of patients
who discontinued treatment because of the need to
take several preparations at the same time. The eco-
nomic aspect in which the lower cost of complex
preparations has a significant impact on improving
the availability of specific therapy, especially in
low-income patients, has also been highlighted.
Referring to results such as blood pressure or lipid
levels, the authors did not observe statistically sig-
nificant differences compared to the control group
taking certain drugs in the form of one-component
pharmaceutical preparations.
The IMPACT study (13) is a randomized study
evaluating the efficacy of a polypill (acetylsalicylic
acid, simvastatin, lisinopril, and either hydrochloro-
thiazide or atenolol) in patients at the high risk of
cardiovascular diseases. The results presented by the
authors showed a great potential of polypills both in
pharmacological and economic aspect (13). The
lack of observed side effects and the greater effec-
tiveness of adherence to the recommendations and
control by patients and physicians may have a sig-
nificant impact on the health status of patients at risk
of complications related to the cardiovascular dis-
ease.
The HOPE-3 study is aimed at assessing
whether rosuvastatin, candesartan and hydrochloro-
thiazide applied in the form of a polypill, or as a sin-
gle pharmaceutical formulation, will have a statisti-
cally significant effect on the reduction of choles-
terol and blood pressure, and can reduce the risk of
heart attack, stroke and their consequences com-
pared to placebo (14).
SECURE is a clinical trial, which is scheduled
for 2020, testing the efficacy of a polypill in a sec-
ondary prevention of cardiovascular diseases, in the
elderly population. It is run in 7 European countries:
Czech Republic, France, Germany, Hungary, Italy,
Poland, and Spain. During studies, it will be
assessed whether the use of a polypill, containing
three active substances of proven efficacy (acetyl-
salicylic acid, atorvastatin and ramipril) will reduce
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the occurrence of major cardiovascular
incidents in patients after acute myocar-
dial infarction (15). Some of the
obtained results have already been pub-
lished and some studies are still carried
out. The results are presented in Table 1.
Analytical methodology
The relatively new topic of the
analysis of pharmaceutical preparations
used in the form of polypills requires the
application of separation techniques in
the majority of cases.
Pawar proposed the RP-HPLC
method for the analysis of a mixture
composed of enalapril maleate, hydr-
ochlorothiazide, acetylsalicylic acid and
atorvastatin (16). The separation was
achieved using Lichrosphere 100 RP-18
reversed phase C18 column (250 ×
4.6 mm, particle size 5 µm). As a mobile
phase, the author used a mixture of
methanol: acetonitrile: triethylammo-
nium phosphate buffer at a flow rate of 
0.6 mL/min. Spectrophotometric detec-
tion was performed at a wavelength of
225 nm. Under these conditions, well-
developed and separated peaks of indi-
vidual components with the retention
times ranging from 3.67 min. to 8.3 min.
were obtained. The method was charac-
terized by a wide linearity range, high
accuracy, and precision. The experimen-
tally determined LOD was 1.474 µg/mL
for acetylsalicylic acid, 0.737 µg/mL for
hydrochlorothiazide, 0.545 µg/mL for
enalapril and 1.641 µg/mL for ator-
vastatin. The LOQ was 4.466 µg/mL,
2.233 µg/mL, 1.653 µg/mL and 4.972
µg/mL, respectively. The composition of
the model mixture was not determined in
this case by a specific quantitative ratio
based on, for example, commonly avail-
able pharmaceutical formulations con-
taining individual ingredients or com-
monly accepted dosage regimens, but
was determined by the validation param-
eters.
Identical mobile-phase in terms of
qualitative composition, changed in
terms of the ratios of the individual com-
ponents, ie. acetonitrile, methanol and
triethylammonium phosphate buffer
were used for the analysis of a mixture
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composed of acetylsalicylic acid, ramipril, metopro-
lol and atorvastatin using the RP-HPLC method.
The quantitative composition of this mixture was
determined by the quantitative ratio of the con-
stituents in the Zycad-4 pharmaceutical formulation
(17). Using Lichrosphere 100 RP-18 reversed phase
C18 column (250 ◊ 4.6 mm, particle size 5 µm),
mobile phase flow rate 0.8 mL/min and spectropho-
tometric detection at 225 nm, the authors obtained a
satisfactory separation of determined components
with retention times of: 4.117 min for acetylsalicylic
acid, 5.90 min for atorvastatin, 7.158 min for
ramipril and 8.333 min for metoprolol. The total
analysis time under the described conditions was 15
min. The tested linearity range was wide and the
LOD value for the individual components was 3.052
µg/mL for acetylsalicylic acid, 3.700 µg/mL for
metoprolol, 1.007 µg/mL for ramipril and
0.961µg/mL for atorvastatin. LOQ was 9.248
µg/mL, 11.213 µg/mL, 3.053 µg/mL and 2.912
µg/mL, respectively. Validation parameters met the
ICH requirements for the chromatographic method.
Recovery for the Zycad-4 pharmaceutical prepara-
tion ranged from 97.8% to 99.76% depending on the
determined component. 
Shetty et al. have proposed an HPLC method
with spectrophotometric detection at 230 nm for the
separation of active substances in the pharmaceuti-
cal preparation called Star pill (Cipla Ltd.), com-
posed of atorvastatin 10 mg, 50 mg of atenolol, 50
mg of losartan and 75 mg of acetylsalicylic acid
(18). The stationary phase was Inertsil ODS C18
column (150 ◊ 4.6 mm, particle size 5 µm), while
the mobile phase was a mixture of buffer and ace-
tonitrile at a flow rate of 1.0 mL/min. Under these
conditions, well separated and developed peaks of
examined substances with the retention times 12.9
min for atorvastatin, 3.3 min for atenolol, 10.7 min
for losartan, and 7.6 min for acetylsalicylic acid,
were determined at the total analysis time of 20 min.
The studied linearity range was wide and ranged
from 5.0 to 20.0 µg/mL for atorvastatin, 37.5 to
150.0 µg/mL for acetylsalicylic acid and 25.0 to
100.0 µg/mL for atenolol and losartan. This choice
of linearity ranges allowed the Star pill ingredients
to be determined with satisfactory statistical values.
Moreover, the authors evaluated the stability of test-
ed substances under different conditions. The
behavior of the substances in acidic medium (0.1
mol/L HCl for 1 h), alkaline medium (0.1 mol/L
NaOH for 2 h), in the presence of oxidants (5%
H2O2, room temperature, 48 h), during the exposi-
tion to light for an overall illumination of 1.2 million
lux hours and an integrated near ultraviolet energy
of 200 watt-hours/square meter and at 60OC for 8 h
was analyzed. Under the studied conditions, it was
found that the most sensitive substances in the case
of hydrolysis in acidic environment were acetylsali-
cylic acid, atenolol and atorvastatin, while in alka-
line environment atenolol and atorvastatin. The
most sensitive substances to oxidants were losartan,
atorvastatin and acetylsalicylic acid. Atorvastatin
and losartan were the most susceptible to photolysis
and atenolol and acetylsalicylic acid to thermolysis.
Based on the publication, it can be stated that ator-
vastatin is the most susceptible to degradation
because its degradation rate in all tested cases was
high, except for the thermal degradation.
In the paper published in the Journal of Pharma-
ceutical Analysis, the authors presented a method for
the quantitative analysis of 10 substances used in dif-
ferent configurations mainly in the treatment of car-
diovascular diseases (19). Due to differences in the
partition coefficients of the individual substances, dif-
ferent variants of the mobile phase composition and
two types of stationary phase were tested. The opti-
mum separation was achieved by using a mobile
phase composed of acetonitrile modified with 0.1%
triethylamine acetate (TEAA) buffer (pH = 5) at a
flow rate of 1 mL/min and UV detection at λ = 230
nm. The stationary phase, in this case, was the chro-
matographic column 5 µm phenyl (250 mm ◊ 4.6 mm
i.d.). When C18 column was used as a stationary
phase, and depending on the modification of the
mobile phase, atenolol and acetylsalicylic acid or
atorvastatin and telmisartan were not resolved. Under
the developed optimum separation conditions, the
well-developed peaks were obtained and the follow-
ing retention times were obtained: metoprolol 4.1
min, atenolol 8.1 min, acetylsalicylic acid 8.5 min,
losartan 10.6 min, telmisartan 12.8 min, atorvastatin
13.6 min, glimepiride 15.9 min, ezetimibe 17.2 min,
clopidogrel 23.8 min. and for fenofibrate 24.4 min.
The tested linearity range for all substances was 50-
150 mg/mL with correlation coefficients greater than
0.9990 in all cases. LOD and LOQ were determined
experimentally and were in the range: LOD from 0.13
to 0.27 µg/mL and LOQ from 0.30 to 0.89 µg/mL,
depending on the tested substance. The developed
procedure was used by the authors for the determina-
tion of active substances occurring in complex drug
formulations. The results did not differ from the
declared by the manufacturer content and the values
of parameters such as recovery and RSD were in all
cases within the criteria of acceptance, recovery of
100% ± 5% and RSD value not exceeding 1.5%.
Another type of a polypill, composed of sim-
vastatin 20 mg, ramipril 5 mg, hydrochlorothiazide
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12.5, atenolol 50 mg and acetylsalicylic acid 100 mg
was quantitatively analyzed by Yadav and Rao (20).
For this purpose, an RP-HPLC method with a
Hypersil ODS C18 column (250 ◊ 4.6 mm, particle
size 5 µm) was used and a mobile phase composed
of methanol: water in the ratio of 95 : 5% v/v at a
flow rate 1 mL/min. In this case, as in many pre-
vious ones, spectrophotometric detection was used
at 230 nm. Such separation conditions allowed the
authors to obtain a relatively short analysis time (12
min) where the retention times of the individual
components were 1.983, 2.525, 3.108, 3.867 and
7.833 min respectively for acetylsalicylic acid,
ramipril, hydrochlorothiazide, simvastatin, and
atenolol. The linearity ranges of the individual com-
ponents were 20-120 µg/mL for acetylsalicylic acid,
1-6 µg/mL for ramipril, 2.5-15 µg/mL for hydro-
chlorothiazide, 4-24 µg/mL for simvastatin, 10-60
µg/mL for atenolol and were adjusted to the ratio of
the individual components in the polypill. The cor-
relation coefficients of all calibration curves were
0.9996, except for the calibration curve for ramipril
whose value was 0.9990. Detection and quantifica-
tion limits were calculated using appropriate mathe-
matical formula and were in the following ranges:
LOD from 0.2 to 6.6 µg/mL, LOQ from 0.5 to 14.0
µg/mL. The authors checked the correctness of the
method by analyzing pharmaceutical preparation
called Polycap and obtained satisfactory results,
confirmed by the statistical analysis. The advantage
of the presented procedure may be a simple compo-
sition of the mobile phase and a short analysis time.
Polytorva capsules were subjected to qualita-
tive and quantitative analysis by RP-LC and RP-
HPLC methods (21-22). These polypills are com-
posed of three active substances, namely ramipril 
5 mg/tablet, acetylsalicylic acid 75 mg/tablet and
atorvastatin 10 mg/tablet. The separation was car-
ried out using a C18 column (250 mm ◊ 4.6 mm,
5µm particle size). The composition of the mobile
phase was very similar, in the LC method a mixture
of 0.1% orthophosphoric acid buffer: acetonitrile:
methanol at pH = 3.3 was used and in the case of
RP-HPLC method, a mixture of acetonitrile:
methanol (65 : 35, v/v) (mixture A) and 10 mM
sodium dihydrogen phosphate monohydrate buffer,
which was adjusted to pH = 3.0 with 10% ortho-
phosphoric acid (mixture B) was used. The two mix-
tures were mixed together in a ratio of 60 : 40 v/v to
obtain a separation that guarantees correct interpre-
tation of the obtained peaks. The total analysis time
of the two methods did not exceed 13 min, and the
detection was carried out with a spectrophotometric
detector at λ = 210 nm (LC) and at 230 nm (RP-
HPLC). Under the developed conditions, a clear
separation of the active substances was achieved,
where the peak area of ramipril was relatively small
compared to the other components. This is probably
due to the mutual quantitative ratio of ingredients in
the studied drug formulations. The retention times
of examined substances were 3.62, 4.92 and 11.71
min. for LC method and 2.34, 3.95 and 12.19 min.
for RP-HPLC method, for ramipril, acetylsalicylic
acid and atorvastatin respectively, and in both cases
were comparable. LOD and LOQ, compared to
other analyzes of samples of similar composition,
were significantly lower. Large differences in their
values depending on the method used (with almost
the same determination conditions and retention
times) can be surprising. In the case of RP-LC, the
authors reported LOD values of 4.71, 85.13 and
29.85 ng/mL, while LOQs were respectively 14.28,
257.97 and 90.45 ng/mL for ramipril, acetylsalicylic
acid and atorvastatin. For RP-HPLC, these values
were LOD: 0.014, 0.100, 0.0095 ng/mL and LOQ:
0.043, 0.329 and 0.029 ng/mL for the respective
substances. Other validation parameters of the
developed method such as accuracy and precision
were within acceptable limits. The content of indi-
vidual components was not significantly different
from the content declared by the manufacturer of the
pharmaceutical preparation.
Identical in terms of quantitative and qualita-
tive composition pharmaceutical preparation was
analyzed by thin-layer chromatography (23). The
chromatographic separation was conducted on
HPTLC plates with fluorescent indicator (silica gel
60, F254). Chromatograms were developed in a chro-
matographic chamber, previously saturated with a
mobile phase, to a distance of 8 cm. The mobile
phase was a mixture of benzene: ethyl acetate:
toluene: methanol: glacial acetic acid. After the
plates were dried, densitometric detection was per-
formed at 220 nm. The obtained densitogram was
characterized by well separated and well-developed
peaks of relatively large areas. RF values were 0.28
± 0.01 for ramipril, 0.45 ± 0.02 for atorvastatin, and
0.72 ± 0.02 for acetylsalicylic acid. The linearity
range of the method was examined in two concen-
tration ranges: 0.5-2.5 µg/spot for ramipril and ator-
vastatin and 0.75-3.75 µg/spot for acetylsalicylic
acid. Validation parameters such as accuracy, preci-
sion or repeatability were comparable to that
obtained by the RP-HPLC method. The determined
content of active substances in the pharmaceutical
preparation was satisfactory (RSD = 99.17-
100.75%). The obtained results revealed, that the
method proposed by the authors may be competitive
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in relation to the RP-HPLC method in terms of costs
but definitely differs in terms of analysis time.
Some authors attempt to determine active sub-
stances that may hypothetically appear in the form
of one tablet because the composition of polypills
used in the treatment of cardiovascular disease may
be different. In this case, two ways of proceeding are
possible. Either the mixture is prepared from stan-
dard substances, taking into account the daily
dosage of the individual ingredients, or ready-made,
commercially available tablets (in the form of one or
two-component formulations) are used after tritura-
tion. This second option was used for the simultane-
ous determination of losartan, hydrochlorothiazide
and atorvastatin (24). For the preparation of the test
samples, the authors used Kanzar-H tablets com-
posed of losartan 100 mg/tablet and hydrochloroth-
iazide 25 mg/tablet, which were powdered with
20 mg of atorvastatin standard substance. The chro-
matographic separation was conducted on a
Hypersil C18 (250 ◊ 4.6 mm, 5 µm particle size)
column at 40OC; the mobile phase was composed of
acetonitrile : 0.2 M phosphate buffer (50 : 50, v/v) at
a flow rate of 1.5 mL/min. As in most cases, an ana-
lytical wavelength of 230 nm was chosen when the
spectrophotometric detector was used. The deter-
mined linearity range was 10-100 µg/mL for losar-
tan, 10-90 µg/mL for hydrochlorothiazide, and 10-
150 µg/mL for acetylsalicylic acid. The correlation
coefficients were in the range from 0.9987 to
0.9993. The retention times of examined substances
were 1.98 min for hydrochlorothiazide, 3.28 min for
losartan and 8.13 for atorvastatin. The determination
results of the individual components in the pow-
dered mixture did not statistically differ from the
declared content (RSD 99.08-99.60%).
Taking into account the way of conducting the
analysis, high scientific value has the work in which,
besides determination of certain substances in drug
formulations, the authors present the possibility of
determination of selected active substances or their
metabolites in biological material. This type of
paper was published in J. Liq. Chromatogr. Related
Technol., where a quantitative analysis of the active
ingredients present in Star Pill (Cipla Ltd.) with the
possibility of their determination in spiked human
plasma was presented (25). Both during the analysis
of pharmaceutical preparation and biological mate-
rial, RP-HPLC with KYATECH HiQ Sil C18 HS
column (250mm ◊ 4.6 mm) and a mobile phase at a
flow rate of 1 mL/min composed of acetonitrile :
0.02 M potassium dihydrogen phosphate buffer (pH
= 3.4) (70 : 30%, v/v) were applied. UV detection
was performed at a wavelength of 236 nm.
Hydrochlorothiazide was used as an internal stan-
dard. Linearity ranges were different depending on
the analyzed material. For the analysis of tablets, the
following linearity ranges were used: 20-120 µg/mL
for atenolol and losartan, 30-180 µg/mL for acetyl-
salicylic acid and 4-24 µg/mL for atorvastatin.
When spiked human serum was analyzed, the lin-
earity ranges were relatively lower and matched
their possible content in biological material. They
were respectively 50-300 ng/mL for atenolol and
losartan, 100-600 and 25-150 ng/mL for acetylsali-
cylic acid and atorvastatin. The retention times of
the substances determined were comparable and in
both cases ranged from 2-6 min. Mathematically
determined limits of detection and limits of quanti-
tation were different because of different linearity
ranges. LOD and LOQ of the assay in pharmaceuti-
cal preparation were in the range of 0.012-0.032
µg/mL and 0.029-0.105 µg/mL, while the LOQ
determined in biological material was in the range
from 25 to 100 ng/mL, depending on the determined
substance.
The issue of quality control of multi-compo-
nent pharmaceutical products such as polypills is not
only aimed at the possibility of simultaneous deter-
mination of individual components, but should also
include issues of possible mutual interactions on
processes such as absorption or degradation. This
subject was taken in the Kumarís publications,
which dealt with the possibility of separating and
identifying the degradation products in multicompo-
nent preparations used in the form of polypills and
described the attempts to determine the degradation
mechanism of atenolol, acetylsalicylic acid and
lisinopril (26, 27). In the study of stability and inter-
actions of the individual components on the degra-
dation process, the authors tested the mixture of
hydrochlorothiazide (alternatively atenolol), lisino-
pril, acetylsalicylic acid and simvastatin (inter-
changeably atorvastatin or pravastatin). The degra-
dation process was carried out in a climatic chamber
for 90 days at 40 ± 1OC at humidity of 75 ± 3%.
After this time, the samples were dissolved in
methanol and analyzed using the Supelco C-8 col-
umn (250 mm ◊ 4.6 mm, particle size 5 µm), oven
temperature at 60OC. The mobile phase at a flow rate
of 1 mL/min was a mixture of acetonitrile: phos-
phate buffer (pH = 2.3). Gradient of the mobile
phase was adjusted to the currently analyzed mix-
ture. The linearity range of the investigated sub-
stances was wide and ranged from 25-250 µg/mL,
and the determination coefficients in all cases were
0.999. The retention times of the ingredients were
about 8 min. for atenolol, 13 min. for hydrochloroth-
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iazide, 20 min for lisinopril, 32 min for acetylsali-
cylic acid, 54 min for pravastatin, 65 min for ator-
vastatin and 72 min for simvastatin. By conducting
the degradation process and then analyzing the
resulting reaction mixture by LC-MS, the authors
observed some regularities. The most stable mix-
tures were those where hydrochlorothiazide was
present instead of atenolol. In the case of hydrochlo-
rothiazide/lisinopril/acetylsalicylic acid/simvastatin
mixtures, practically no degradation or interaction
effects were observed. In the mixture of similar
composition in which simvastatin was replaced with
atorvastatin, only one degradation product was
observed, and in the case where the statin was
pravastatin there were six degradation products. In
this case, the authors suggested the possibility of
catalytic action of pravastatin on the degradation
processes of other substances. Significant degrada-
tion and interaction of the substances were observed
in the mixtures with atenolol. When hydrochloroth-
iazide was replaced with atenolol in the mixture,
there was a sharp increase in the number of peaks
resulting from the degradation products or from the
interactions of the individual components. In the
case of statins, simvastatin or atorvastatin, addition-
al peaks deriving from ingredients other than those
originally present in the mixture were twelve, in the
case of pravastatin thirteen. This suggests a very
high effect of atenolol on the stability of other sub-
stances that may be present in one formulation in the
form of a polypill. Continuing their work, the
authors attempted to determine the degradation
pathways and the resulting degradation or interac-
tion products in a mixture containing lisinopril,
atenolol and acetylsalicylic acid. For this purpose,
the LC-MS/TOF method was used using similar
degradation parameters as described previously. As
a result of the analysis five degradation products of
atenolol and lisinopril were detected. In the case of
atenolol, three of them were identified (N-acetyl
atenolol, O-acetyl atenolol and N,O-diacetyl
atenolol) as degradation products while the other
two were found to be interaction products of N-
acetyl atenolol with salicylic acid and atenolol
impurity described in the European Pharmacopoeia
(Fig. 1).
Lisinopril under the described conditions
degraded to Ní-acetyl lisinopril, N,Ní-diacetyl
lisinopril, and two products of cyclization of dike-
topiperazine and N-acetyl diketopiperazine lisino-
pril (Fig. 2).
A manuscript describing the analysis of a mix-
ture of amlodipine, valsartan and hydrochloroth-
iazide was published in 2017 (28). In the article the
authors described the method of separation of the
mixture and attempted to investigate the stability of
the tested substances under different conditions.
Zorbax SB-C8 column was used (4.6 ◊ 250 mm, 
5 µm particle size) for the analysis. A number of sta-
tionary phase modifications were studied and the
Figure 1. Products of degradation and interaction of atenolol
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best separation was obtained using a mixture of
0.025 M phosphoric acid: acetonitrile using a linear
concentration gradient at a flow rate of 1 mL/min.
Detection was performed at 238 nm and 225 nm.
The linearity range of the described procedure was
5-200 µg/mL for amlodipine and valsartan and 10-
200 µg/mL for hydrochlorothiazide. The analysis
time did not exceed 10 min and the retention times
were 4.89, 6.42 and 8.29 min for hydrochloroth-
iazide, amlodipine and valsartan, respectively. The
stability studies were performed in different media
and under different conditions. Degradation in
acidic and alkaline environments was carried out
using 0.1 mol/L HCl or NaOH solutions at 90OC for
1 h. In the case of amlodipine, the degradation time
was reduced to 10 min and the temperature to 60OC
for basic hydrolysis. Oxidative degradation was car-
ried out in 5% H2O2 solution at 80OC for 60 min, and
in the case of amlodipine the time was extended to
120 min. The photodegradation process was carried
out in solid phase by irradiation the powdered sub-
stances in UV at a wavelength of 254 nm. for 60 h.
Similarly, the substances in solid phase were sub-
jected to the temperature of 90OC for 18 h to deter-
mine the effect of high temperature on the stability
of the tested substances. Then the solid samples
were dissolved, analyzed and chromatographic
analysis showed that the lowest stability of the test-
ed substances was found in the acidic medium.
Under these conditions, amlodipine showed degra-
dation in about 30%, and five degradation products
with retention times of 3.18, 3.40, 4.03, 6.06, and
8.87 min. were detected. In case of valsartan, 2
degradation products with retention times of 3.34
and 9.17 min were present and the substance was
degraded in about 50%. Hydrochlorothiazide proved
to be the least stable, its degradation rate was high
and reached 75%. In the chromatogram one addi-
tional peak with a retention time of 4.53 min. was
observed. The degradation process in alkaline medi-
um was the greatest for amlodipine (35%) and
hydrochlorothiazide (30%) but for valsartan the
degradation rate reached 13%. Amlodipine was
found to have two additional peaks of degradation
products (5.08 min, 6.04 min) and hydrochloroth-
iazide had one additional peak (4.53 min). No addi-
tional peaks of degradation products were found for
valsartan. The highest sensitivity to oxidation was
observed in the case of valsartan (degradation rate
about 40%), lower in the case of hydrochloroth-
iazide (30%). The most stable substance under these
conditions was amlodipine with degradation rate
about 25%. Analysis of chromatograms registered
for amlodipine and hydrochlorothiazide revealed the
presence of one additional peak deriving from the
degradation product at a retention time of 6.02 min.
Figure 2. Products of degradation and cyclization of lisinopril
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for amlodipine and 4.53 min for hydrochloroth-
iazide. Valsartan showed the greatest number of
degradation products with retention times of 7.49,
7.65, 7.85 and 8.04 min. The highest stability of the
tested substances was observed in the case of pho-
todegradation and thermo-degradation processes.
The most susceptible to photodegradation was
hydrochlorothiazide (about 13%) showing three
additional peaks (4.53 min, 6.69 min, 8.85 min).
Valsartan, with a degradation rate of about 6% had
three additional peaks at retention times 7.88 min,
9.22 min, 9.57 min. Amlodipine did not undergo
photodegradation under the described conditions.
The highest stability of the tested substances was
observed in the case of thermo-degradation, only
valsartan was degraded in 5% and one additional
peak appeared at 4.38 min.
Another publication describing the stability
studies of active substances that may be in the form
of FDC is paper published in the Indian Journal of
Pharmaceutical Sciences (29). The authors pro-
posed chromatographic conditions for the separa-
tion of a mixture containing atenolol, acetylsali-
cylic acid, lisinopril and simvastatin, which was
subjected to stress tests during the experiment. The
mobile phase was a mixture of 0.05 M phosphate
buffer pH = 2.5 adjusted with dilute phosphoric
acid and acetonitrile, and gradient elution was
applied. The separation was conducted on a
Hypersil BDS C8 column during 25 min. The sepa-
ration proved to be satisfactory, and characterized
by well separated peaks with retention times of 3.97
min for atenolol, 5.82 min for lisinopril, 9.49 min
for acetylsalicylic acid and 18.36 min for simvas-
tatin. The tested linearity range was wide for all
substances and was 12.5 to 75 µg/mL for atenolol,
2.5 to 15 µg/mL for lisinopril, 18.75 to 112.5 µg/mL
for acetylsalicylic acid and 5 to 30 µg/mL for sim-
vastatin. The linearity ranges included average
daily doses of particular substances commonly used
in therapy. In all cases, the correlation coefficient
was high (r > 0.999). The degradation process of
the tested substances was carried out under differ-
ent conditions: heat (60OC) ñ 10 days, acid (5.0
mol/L HCl at 27OC) ñ 40 h, base (5.0 mol/L NaOH
at 27OC) ñ 30 h and oxidation (2% H2O2 at 27OC) ñ
2 h. The chromatograms registered after the degra-
dation process showed the presence of additional
peaks; in thermal degradation there were 7 peaks
and in other cases 6. Comparing the retention times
presented by the authors, it can be seen that the for-
mation of some products is not strictly determined
by the application of certain degradation conditions
for active substances.
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Micellar electrokinetic capillary chromato-
graphic method has been successfully used for the
quantitative analysis of laboratory-made polypills
containing lisinopril, hydrochlorothiazide, acetylsal-
icylic acid and atorvastatin as active substances
(30). The separation was run using silica capillary
(58 cm, 75 mm ID) and a background electrolyte
solution consisting of borax buffer (20 mM, pH =
9.5) containing 30 mM sodium lauryl sulphate and
paracetamol as an internal standard, voltage up to 25
kV. The capillary was conditioned prior to injection
for a suitable time using 0.1 M sodium hydroxide,
water and running buffer. Under these conditions,
the authors checked the linearity range and for all
substances it was in the range of 0.1-200 µg/mL.
The determined correlation coefficient was high (r >
0.999) and limits of detection and quantitation were
in the following ranges: LOD 0.33-3.1 µg/mL, and
LOQ 1.1-10.32 µg/mL depending on the substance.
The retention times presented in the cited work
were: ~ 4 min for paracetamol (IS), 4.10 min for
lisinopril, 4.25 min. for hydrochlorothiazide, 4.50
min for acetylsalicylic acid, 5.25 min for salicylic
acid as possible impurity of acetylsalicylic acid and
~ 8.15 min for atorvastatin. The statistical parame-
ters of the developed method proved its high accu-
racy and precision. The composition of preparations,
the analytical techniques used and their basic param-
eters are summarized in Table 2.
CONCLUSIONS
In the presented paper, the authors summarize
the analytical methods described in the literature
with particular reference to their use in fixed-dose-
combination (FDC) product analysis, polypills, used
in the treatment of hypertensive disease. Some of the
preparations described in the review have undergone
clinical trials, and some clinical studies are still
being conducted. Due to the increasing number of
preparations that can be classified as FDC and the
mostly favorable opinions of patients and physicians
and representatives of the pharmaceutical industry
who have come in contact with such targeted thera-
pies, gathering and describing analytical methods
that can be used in quantitative analysis (both in
quality control and in stability studies of compo-
nents) seemed to be important. 
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